AtrásBouygues CEO Warns Europe Against Over-Reliance on U.S. Infrastructure, Citing Starlink Risks

NOTICIA

CNBC World21/5/2026Business

Bouygues CEO Warns Europe Against Over-Reliance on U.S. Infrastructure, Citing Starlink Risks

Bouygues Starlink SpaceX

En resumen

Bouygues CEO Olivier Roussat warns Europe against relying on U.S. infrastructure, particularly Elon Musk's Starlink, citing sovereignty and vulnerability risks.
This comes as Bouygues leads a €20.35 billion bid for SFR, aiming to consolidate France's telecom market.

Resumen generado por IA

Tamaño de fuente

Bouygues CEO Olivier Roussat warns Europe against relying on U.S. infrastructure, particularly Elon Musk's Starlink, citing sovereignty and vulnerability risks. This comes as Bouygues leads a €20.35 billion bid for SFR, aiming to consolidate France's telecom market.

Read the full article on CNBC World

Temas relacionados

Bouygues

TemasStarlink SpaceX Elon Musk European Telecom Consolidation SFR

This article was originally published by CNBC World.

Noticias relacionadas

Más sobre este temaBouygues

Business·hace 12 horas

Apple Remains Market Safe Haven, Two Earnings Play Strategies

Apple hits new all-time highs as a market safe haven. Ahead of Q4 earnings, options imply a modest 3.8% post-earnings move. Two strategies outlined: a low-cost hedge for long holders and defined-risk call buys for prospective bulls.

CNBC World

2 min de lectura

Business·hace 14 horas

UBS Reports Q2 Profit Rise Amid Geopolitical Volatility Warnings

UBS posts $2.8B Q2 net profit, in line with forecasts, with CEO Sergio Ermotti cautioning on geopolitical volatility while highlighting strong business momentum and a 'vibrant' IPO market.

CNBC World

2 min de lectura

Business·hace 15 horas

Cracker Barrel CEO Julie Masino Steps Down Amid Branding Backlash

Cracker Barrel CEO Julie Masino is leaving after a year of controversy over the chain's branding modernization, which sparked a 'woke' backlash on social media, leading to a logo reversal and a 3% stock drop upon her departure announcement.

Guardian Business

3 min de lectura

Business·hace 16 horas

Novo Nordisk Shareholders Sue Over Obesity Drug CagriSema Trial Disclosure

Novo Nordisk faces a lawsuit from shareholders alleging misleading statements about its obesity drug CagriSema's clinical trial, leading to a significant market value drop. A federal judge has allowed parts of the lawsuit to proceed.

CNBC World

5 min de lectura

Business·hace 16 horas

AstraZeneca Urged to Adopt 'Chinese Speed' to Avoid Automotive Industry's Fate

AstraZeneca's CEO Pascal Soriot warns the company must innovate at 'Chinese speed' to compete with emerging pharmaceutical rivals, citing the automotive industry's loss to Chinese electric vehicle dominance. Despite confidence in hitting $80bn 2030 sales targets, Soriot acknowledges the threat from Chinese innovators in novel drug technologies.

Guardian Business

5 min de lectura

Business·ayer

Johnson & Johnson to Pay Estimated $5.5 Billion in Talc Settlement

Johnson & Johnson agrees to pay up to $5.5 billion to settle nearly 76,000 lawsuits alleging its talc products caused ovarian cancer, ending a decade-long legal battle.

Guardian Business

3 min de lectura

Más sobre este temaBouygues